Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 285

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 285
---
 $30.40.

On September 28, 2023, the Company extended
the exercise period until December 31, 2023.

On January 3, 2024, the Company extended
the due date of 2020 Notes until April 30, 2024 (which was later extended to May 27, 2024).

The Company estimates the fair value of
the warrant using PWERM. For the years ended December 31, 2023 and 2022, the Company recorded an income of $5 and an expense of $270,
respectively, for the revaluation of such warrants, within financial expense, net in the statements of comprehensive loss.

A summary of significant unobservable
inputs (Level 3 inputs) used in measuring the fair value of the warrants issued are as follows:

|               |     |   | December 31, 
         2023 |   |     |   | December 31, 
         2022 |   |
|:--------------|:----|:--|-------------:|:--|:----|:--|-------------:|:--|
| Discount rate |     |   |         30.0 | % |     |   |         30.0 | % |
| Term (years)  |     |   |         0.25 |   |     |   |          0.5 |   |
| Fair value    |     | $ |          402 |   |     | $ |          407 |   |

<div align='center'>F-34</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | WARRANT LIABILITY (Cont.) |

The following table presents changes in
the fair value of the warrant liability:

| Balance as of January 1, 2022   |     | $ | 137 |   |
| Changes in fair value           |     |   | 270 |   |
| Balance as of December 31, 2022 |     | $ | 407 |   |
| Changes in fair value           |     |   |  (5 | ) |
| Balance as of December 31, 2023 |     | $ | 402 |   |

The Company has performed a sensitivity
analysis of the warrant liability which is classified as level 3 financial instruments in the fair value hierarchy. The Company